Adaptive Biotechnologies vs Vir Biotechnology
ADPT and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADPT and VIR compare
Adaptive Biotechnologies is the larger company, worth 2.7 times as much as Vir Biotechnology ($4.6B against $1.7B).
Vir Biotechnology grew revenue faster over the last twelve months (1696% versus 17.9% for Adaptive Biotechnologies).
Adaptive Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −23.7% compared with −61.0% at Vir Biotechnology.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADPT | VIR |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $1.7B |
| Share price | $29.04 | $9.96 |
| Change, 1 year | 100% | 74.4% |
| Change, 5 years | 6.2% | −69.6% |
| Beta (5Y) | 1.79 | 0.72 |
| Employees | 624 | 367 |
| StockData Score | ||
| Total score | 12 | 12 |
| Valuation score | 0 | 3 (better) |
| Growth score | 4 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.6× | 5.6× (better) |
| P/B | 26.3× | 1.9× (better) |
| FCF yield | −0.19% (better) | −8.4% |
| Fair value | $6.88 | $12.60 |
| Margin of safety | −322% | 21.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 17.9% | 1696% (better) |
| Revenue growth, 5Y average | 23.0% (better) | −2.1% |
| Profitability | ||
| Gross margin | 74.2% | – |
| Operating margin | −16.2% (better) | −69.8% |
| Net margin | −23.7% (better) | −61.0% |
| FCF margin | −3.0% (better) | −46.8% |
| Return on equity | −37.1% | −21.8% (better) |
| Return on invested capital | −9982% | −45.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −5.3× | – |
| Current ratio | 3.97 | 6.30 (better) |
| Altman Z-score | 3.38 (better) | 3.11 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.6% | 86.6% |
| Held by insiders | 22.7% | 17.0% |
| Insider net buying, 12 months | −$117M | −$4.0M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | 12.0% |
Go deeper
- ADPT stock overview
- ADPT income statement
- ADPT valuation and score
- VIR stock overview
- VIR income statement
- VIR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.